NRx Pharmaceuticals announces data on in vitro activity of NRX-101

NRx Pharmaceuticals announced new data that demonstrate potent in vitro activity of NRX-101 against reference strains of Urinary Tract pathogens known to cause complicated urinary tract infections. D-cycloserine was originally developed as an anti-infective in the 1950’s but was never labeled for treatment of UTI, because of the prevalent and then-effective use of common antibiotics. In recent years, however, cUTI is increasingly caused by pathogens that are resistant to common antibiotics and are increasingly likely to cause sepsis, a lethal condition. Approximately 17,000 deaths per year in the United States are attributed to genitourinary sepsis. The study, commissioned by NRx at Charles River Laboratories, is consistent with previously reported academic studies that demonstrate potency of DCS in antibiotic-resistant strains of urinary pathogens. If successfully developed, NRX-101 could offer cUTI patients an effective therapy with a favorable safety profile. Because NRx has already completed the phase 3 manufacture of NRX-101, the Company is in a position to immediately seek investigational human use for this indication, while continuing to develop NRX-101 for suicidal depression and chronic pain.